✨ Medicines and Health Appointments




20 DECEMBER 2007 NEW ZEALAND GAZETTE, No. 142 3691

Schedule

Product:
Cymbalta
Active Ingredient:
Duloxetine hydrochloride 33.7mg equivalent to duloxetine base 30mg
Dosage Form:
Modified release capsule
New Zealand Sponsor:
Eli Lilly and Company (NZ) Limited
Manufacturer:
Eli Lilly and Co, Lilly Technology Centre, Indianapolis, Indiana, United States of America

Product:
Cymbalta
Active Ingredient:
Duloxetine hydrochloride 67.3mg equivalent to duloxetine base 60mg
Dosage Form:
Modified release capsule
New Zealand Sponsor:
Eli Lilly and Company (NZ) Limited
Manufacturer:
Eli Lilly and Co, Lilly Technology Centre, Indianapolis, Indiana, United States of America

Product:
Hexal Ranitidine Forte
Active Ingredient:
Ranitidine hydrochloride 336mg equivalent to ranitidine 300mg
Dosage Form:
Film coated tablet
New Zealand Sponsor:
Novartis New Zealand Limited
Manufacturer:
Salutas Pharma GmbH, Barleben, Germany

Product:
Pfizer Ranitidine 24 Hour Action
Active Ingredient:
Ranitidine hydrochloride 336mg equivalent to ranitidine 300mg
Dosage Form:
Film coated tablet
New Zealand Sponsor:
Novartis New Zealand Limited
Manufacturer:
Salutas Pharma GmbH, Barleben, Germany

Product:
Sumatriptan
Active Ingredient:
Sumatriptan succinate 140mg equivalent to 100mg sumatriptan
Dosage Form:
Film coated tablet
New Zealand Sponsor:
REX Medical Limited
Manufacturer:
Cipla Limited, Manufacturing Division, Verna Industrial Area, Salcette Goa, India

Product:
Sumatriptan
Active Ingredient:
Sumatriptan succinate 70mg equivalent to 50mg sumatriptan
Dosage Form:
Film coated tablet
New Zealand Sponsor:
REX Medical Limited
Manufacturer:
Cipla Limited, Manufacturing Division, Verna Industrial Area, Salcette Goa, India

Dated this 13th day of December 2007.

ANTHONY HILL, Deputy Director-General, Sector Accountability and Funding Directorate (pursuant to delegation given by the Minister of Health on 6 July 2001).

go8733

Renewal of Provisional Consent to the Distribution of a New Medicine

Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicine set out in the Schedule hereto:

Schedule

Product:
Avastin
Active Ingredient:
Bevacizumab 100mg
Dosage Form:
Concentrate for infusion
New Zealand Sponsor:
Roche Products (New Zealand) Limited
Manufacturers:
F Hoffmann-La Roche Limited, Basel, Switzerland
Genentech Inc, South San Francisco, California, United States of America

Note: This consent is valid for two years from 15 December 2007.

Dated this 13th day of December 2007.

ANTHONY HILL, Deputy Director-General, Sector Accountability and Funding Directorate (pursuant to delegation given by the Minister of Health on 6 July 2001).

go8732

New Zealand Public Health and Disability Act 2000

Appointment to the Quality Improvement Committee

Pursuant to section 11 of the New Zealand Public Health and Disability Act 2000, I appoint

Dr Nicholas Baker

as an ex officio member to the Quality Improvement Committee for a term of office commencing 17 December 2007 and ending 28 February 2010.

Dated at Wellington this 6th day of December 2007.

HON. DAVID CUNLIFFE, Minister of Health.

go8717



Next Page →



Online Sources for this page:

VUW Te Waharoa PDF NZ Gazette 2007, No 142


Gazette.govt.nz PDF NZ Gazette 2007, No 142





✨ LLM interpretation of page content

πŸ₯ Consent to the Distribution of New Medicines (continued from previous page)

πŸ₯ Health & Social Welfare
13 December 2007
Medicines, Consent, Distribution, Cymbalta, Hexal Ranitidine Forte, Pfizer Ranitidine, Sumatriptan
  • ANTHONY HILL, Deputy Director-General, Sector Accountability and Funding Directorate

πŸ₯ Renewal of Provisional Consent to the Distribution of a New Medicine

πŸ₯ Health & Social Welfare
13 December 2007
Medicines, Renewal, Provisional Consent, Avastin
  • ANTHONY HILL, Deputy Director-General, Sector Accountability and Funding Directorate

πŸ₯ Appointment to the Quality Improvement Committee

πŸ₯ Health & Social Welfare
6 December 2007
Appointment, Quality Improvement Committee, Dr Nicholas Baker
  • Nicholas Baker (Doctor), Appointed to Quality Improvement Committee

  • HON. DAVID CUNLIFFE, Minister of Health